Dudediligence.

Inhibikase Therapeutics, Inc

IKTNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Price
FilingsNewest: 8-K, Regulation FD disclosureSep 8 →Insiders3 insiders bought $3.0M in 1 open-market buy. No sales.→HoldersSands Capital Alternatives 9.9%Soleus 8.2%Trails Edge Capital Partners 6.9%→Financing →PeersClosest companies: PRLD, FULC, ELVN→

From the filings

Figures

Net income
−$60.6Mlast 12 months
Operating cash flow
−$35.7Mlast 12 months
Cash and equivalents
$31.2Mat the last balance sheet
Total debt
$0.00at the last balance sheet
Shares outstanding
132.0M shareson issue
Every year and quarter →